Novartis Ag (NVS) Tax Provisions (2009 - 2026)

Novartis Ag (NVS) has 8 years of Tax Provisions data on file, last reported at -$683.0 million in Q1 2026.

• Quarterly Tax Provisions rose 14.41% year-over-year to -$683.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.3 billion (down 10.3% YoY) and the FY2025 annual result came in at $2.4 billion, up 40.21% from the prior year.
• Tax Provisions grew to -$683.0 million in Q1 2026 per NVS's latest filing, from -$814.0 million in the prior quarter.
• The five-year high for Tax Provisions was $261.0 million in Q4 2023, with the low at -$814.0 million in Q4 2025.
• Average Tax Provisions over 5 years is -$389.9 million, with a median of -$403.0 million recorded in 2023.
• Year-over-year, Tax Provisions surged 202.76% in 2023 and sank 412.82% in 2024.
• Novartis Ag's Tax Provisions stood at -$254.0 million in 2022, then surged by 202.76% to $261.0 million in 2023, then tumbled by 278.16% to -$465.0 million in 2024, then sank by 75.05% to -$814.0 million in 2025, then advanced by 16.09% to -$683.0 million in 2026.
• Business Quant data shows NVS's Tax Provisions at -$683.0 million in Q1 2026, -$814.0 million in Q4 2025, and -$266.0 million in Q3 2025.